Amplius Wealth Advisors, LLC Corvus Pharmaceuticals, Inc. Transaction History

Amplius Wealth Advisors, LLC

  • $851 Million
  • Q3 2025

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 09, 2022
SELL
$1.46 - $2.48 $855 - $1,453
-586 Closed
0 $0
Q4 2021

Jan 28, 2022
BUY
$2.34 - $5.31 $1,371 - $3,111
586 New
586 $1,000

About Corvus Pharmaceuticals, Inc.

CRVS Quotes by TradingView
  • Ticker CRVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,553,500
  • Market Cap $408M
  • Description
  • Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...
More about CRVS
Track This Portfolio

Track Amplius Wealth Advisors, LLC Portfolio

Follow Amplius Wealth Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amplius Wealth Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Amplius Wealth Advisors, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email